Active	Status	Sponsor type	Region	Phase	Filter
7 Active 4 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
TRAN, Tu Anh
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	06/27	11/30
Goverde, Peter P
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
TRAN, Tu Anh
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	06/27	11/30
Goverde, Peter P
No trials found